...
首页> 外文期刊>Haematologica >Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia | Haematologica
【24h】

Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia | Haematologica

机译:结合使用逆转录酶聚合酶链反应和流式细胞术研究费城阳性急性淋巴细胞白血病的最小残留疾病血液学

获取原文

摘要

BACKGROUND AND OBJECTIVES: The Philadelphia chromosome in acute lymphoblastic leukemia (Ph+ ALL) is associated with a poor prognosis given the high frequency of chemoresistance and leukemia relapse. Minimal residual disease (MRD) detection before cytogenetic and hematologic relapse could be useful in early therapy. The most suitable methods for detecting MRD in Ph+ ALL are flow cytometry (FC) and reverse transcriptase polymerase chain reaction (RT-PCR). However, since both techniques carry the risk of false-negative results the combined use of these two techniques could overcome this problem. DESIGN AND METHODS: We report our experience using this approach in 47 bone marrow samples obtained from 10 Ph+ ALL patients. Twenty-seven marrow aspirates were taken from patients in clinical remission (CR). The samples were considered positive for MRD by FC when two conditions were met: 1) detection of an abnormal B-cell differentiation pattern and 2) presence of more than 1x10(-3) cells coexpressing CD22/CD34/CD45 or CD66/CD34/CD10. After FC analysis, RNA was purified using standard methods. RESULTS: FC was positive in 23/27 samples in CR (sensitivity 85%). RT-PCR was successfully performed in 23 samples in CR. RT-PCR was positive in 18/23 samples (sensitivity 78%). There were 5 samples with discordant results. FC was positive in 3 samples with a negative RT-PCR and FC was negative in 2 samples with a positive RT. All the 10 patients relapsed and only 1 is currently alive after an allogeneic stem cell transplantation (alloSCT). The median (range) time from MRD detection to relapse in patients treated with chemotherapy was 42 (39-71) days. INTERPRETATION AND CONCLUSIONS: These data suggest that RT-PCR may be negative despite the presence of neoplastic cells identified by their immunophenotypic traits. We conclude that immunologic and molecular techniques can be used in tandem for monitoring MRD in Ph+ ALL.
机译:背景与目的:鉴于化学抗药性和白血病复发的频率很高,急性淋巴细胞白血病(Ph + ALL)的费城染色体与预后不良有关。在细胞遗传学和血液学复发之前进行最小残留病(MRD)检测可能对早期治疗有用。在Ph + ALL中最适合检测MRD的方法是流式细胞仪(FC)和逆转录酶聚合酶链反应(RT-PCR)。但是,由于这两种技术都具有出现假阴性结果的风险,因此将这两种技术结合使用可以克服此问题。设计与方法:我们报告了从10名Ph + ALL患者获得的47种骨髓样品中使用这种方法的经验。从临床缓解期(CR)的患者中抽取了27个骨髓抽吸物。当满足两个条件时,样品被FC认为是MRD阳性:1)检测异常B细胞分化模式和2)共表达CD22 / CD34 / CD45或CD66 / CD34 /的1x10(-3)细胞以上CD10。 FC分析后,使用标准方法纯化RNA。结果:CR中23/27个样本中FC阳性(敏感性85%)。 RT-PCR成功地在CR的23个样品中进行。 RT-PCR在18/23个样品中呈阳性(灵敏度为78%)。有5个样本的结果不一致。 RT-PCR阴性的3个样本中FC阳性,RT阳性的2个样本中FC阴性。所有10例患者均复发,同种异体干细胞移植(alloSCT)后目前只有1例存活。从MRD检测到接受化疗的患者复发的中位(范围)时间为42(39-71)天。解释和结论:尽管存在通过免疫表型特征鉴定出的肿瘤细胞,但这些数据表明RT-PCR可能为阴性。我们得出结论,可以将免疫学和分子技术串联使用以监测Ph + ALL中的MRD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号